[Skip to Content]
[Skip to Content Landing]
October 8, 1973

The Future of Pharmacotherapy New Drug Delivery Systems

JAMA. 1973;226(2):208. doi:10.1001/jama.1973.03230020050035

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


This reviewer has always gained new knowledge from the writings of Dr. Ayd. This volume is no exception. Dr. Ayd and his group ably present their data and their views on longacting antipsychotic drugs. Emphasis is placed on the extreme need for long-acting depot injectable neuroleptics.

The injectable single-depot dose, lasting for weeks, may comprise only 1% or less of the oral dose required to maintain the psychotic patient in an ambulatory state outside the hospital. Twenty percent of the psychotic patients, including those who are orhave been in mental hospitals, do not take their neuroleptic medication. It is this group of drug defectors that most frequently require readmission to the hospital. The contributors to the book show that psychotics of all age groups, with both acute and chronic disturbances, can be treated effectively and economically. The data primarily deal with depot fluphenazine enanthate and fluphenazine decanoate. Dr. Ayd predicts